Relation of Serum α- and γ-Tocopherol Levels to Cardiovascular Disease-Related Mortality Among Japanese Men and Women

Masanori Nagao1,2, Yuri Moriyama3, Kazumasa Yamagishi4, Hiroyasu Iso1, and Akiko Tamakoshi5, for the JACC Study Group

1Public Health, Department of Social and Environmental Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
2Department of Public Health, Dokkyo Medical University School of Medicine, Shimotsuga, Tochigi, Japan
3Public Health Institute of Kochi Prefecture, Kochi, Japan
4Department of Public Health Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
5Department of Public Health, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan

Received January 12, 2012; accepted February 14, 2012; released online May 19, 2012

Abstract

Background: There is limited evidence regarding the relationship between serum tocopherol levels and cardiovascular disease.

Methods: We conducted a nested case-control study as part of the Japan Collaborative Cohort Study for evaluation of cancer risk (JACC Study). Baseline serum samples were collected from 39,242 participants (age range, 40–79 years) between 1988 and 1990. During the 13-year follow-up, there were 530 stroke deaths (302 ischemic strokes and 210 hemorrhagic strokes) and 211 deaths from coronary heart disease. Controls were matched for sex, age, and area of residence.

Results: Serum α-tocopherol level was not associated with any type of cardiovascular death in men; however, in women, it was inversely associated with total stroke mortality and hemorrhagic stroke mortality. The multivariate odds ratio (95% CI) for the highest versus the lowest quintile of serum α-tocopherol levels among women was 0.35 (0.16–0.77; \( P \) for trend = 0.009) for total stroke and 0.26 (0.07–0.97; \( P \) for trend = 0.048) for hemorrhagic stroke. Serum γ-tocopherol was inversely associated with ischemic stroke mortality in men but positively associated with hemorrhagic stroke mortality in women. The respective multivariate odds ratios (95% CI) for the highest versus the lowest quintile and for a 1-standard deviation increment in γ-tocopherol level were 0.48 (0.22–1.06; \( P \) for trend = 0.07) and 0.77 (0.58–1.02), respectively, for ischemic stroke in men and 3.10 (0.95–10.12; \( P \) for trend = 0.052) and 1.49 (1.04–2.13) for hemorrhagic stroke in women.

Conclusions: Among women, hemorrhagic stroke mortality was inversely associated with serum α-tocopherol and positively associated with serum γ-tocopherol. These findings are due in part to the antioxidative and antithrombotic activities of these tocopherols.

Key words: α-tocopherol; γ-tocopherol; vitamin E; prospective study; stroke; cardiovascular disease; nested case-control study

Introduction

Tocopherols are believed to be promising agents for reducing the risk of cardiovascular disease, due of their strong antioxidant activity.1 Although randomized control trials (RCTs) of tocopherol supplementation have been conducted,2–7 the results have been inconsistent. Several, but not all, RCTs have shown a beneficial effect of α-tocopherol supplementation on the risk of nonfatal myocardial infarction,2 subarachnoid hemorrhage,3 ischemic stroke,3 hemorrhagic stroke,4 and cardiovascular disease mortality.5 RCTs are useful for establishing causality, especially in evaluations of the short- and moderate-term effects of drugs. However, it is difficult to implement RCTs of the effects of long-term dietary exposure. Thus, observational studies are a useful alternative.
Previous observational studies reported an association between intake of tocopherol, either from food or via supplementation, and cardiovascular disease risk.\textsuperscript{8–12} However, pharmacokinetic studies suggest that complex mechanisms are involved in the regulation of tocopherol levels.\textsuperscript{13} For example, large consumption of vitamin E induces excretion of vitamin E via the pregnane X receptor drug metabolism system activated by vitamin E.\textsuperscript{14–16} In contrast, some nutrients, such as sesamin, increase blood tocopherol levels by suppressing tocopherol metabolism.\textsuperscript{17} Thus, tocopherol intake is not always reflected in serum tocopherols levels. For these reasons, we estimated serum levels of tocopherols and examined their relationship with cardiovascular disease risk. Although previous studies have examined the relationship of serum levels of \( \alpha \)- and \( \gamma \)-tocopherol with cardiovascular disease risk in men,\textsuperscript{18–22} no such studies have been conducted in women.

In this nested case-control study using a large prospective cohort of approximately 40 000 men and women, we evaluated the association of serum levels of \( \alpha \)- and \( \gamma \)-tocopherol with the risk of cardiovascular disease mortality among Japanese men and women.

**METHODS**

**Survey population**

We conducted a nested case-control study as part of the Japan Collaborative Cohort (JACC) Study. The methods of the JACC Study have been previously described. In brief, 110 792 individuals (46 465 men and 64 327 women) aged 40 to 79 years during the baseline period (1988–1990) were enrolled from 45 communities throughout Japan. Using self-administered questionnaires, participants gave information on their lifestyle and medical histories of cardiovascular disease and cancer.\textsuperscript{23,24}

Written or explicit verbal informed consent to participate in the study was obtained from the individuals who completed the questionnaire. In several communities, informed consent was obtained at a community level after the purpose and methods of the study and its emphasis on data confidentiality had been explained to community leaders and mayors on behalf of the individual participants. At the time of recruitment for this study, this was a common method of obtaining informed consent in Japan.

A total of 39 242 participants (35.4% of the questionnaire respondents) agreed to provide blood samples and gave individual informed consent.\textsuperscript{25,26} After exclusion of 457 men and 627 women with a history of heart disease, stroke, or cancer at the baseline survey, a total of 38 158 participants (13 382 men and 24 776 women) were enrolled in the present study. The ethics committees of the University of Tsukuba and Osaka University approved the present study.

**Mortality surveillance**

The participants were followed up to determine mortality due to cardiovascular disease until the end of 2003, except for 4 communities in which follow-up ended in 1999.

The study investigators conducted a systematic review of death certificates in each community. Because registration of death is a legal requirement throughout Japan, the investigators were confident of completing the follow-up. Participants who had moved out of their original community were treated as censored cases.

To determine cause-specific mortality of cardiovascular disease, we used the International Classification of Diseases (ICD), 9th and 10th revisions, as follows: total stroke (ICD 9th revision, codes 430–438 and ICD 10th revision, codes I60–I69); coronary heart disease (410–414, I20–I25). Total stroke was subdivided into hemorrhagic stroke (430–431, I60–I61) and ischemic stroke (433–434, I63). For each case, we randomly selected 1 control participant (ie, a person without death from stroke or coronary heart disease) from the participants. Controls were matched for sex, age (±5 years), community, tocopherol measurement method, and year of blood drawing.

**Determination of biochemical variables**

Venous blood was collected at baseline, and sera were prepared from blood samples as soon as possible after blood collection at laboratories in or near the surveyed municipalities. The serum samples were collected in 0.3-ml tubes and stored at −80°C until further use. Serum \( \alpha \)-tocopherol and \( \gamma \)-tocopherol levels were measured using high-performance liquid chromatography (HPLC) at the Osaka laboratory facility of SRL, Inc. (Tokyo, Japan; 246 case-control pairs) and the Public Health Institute of Kochi Prefecture (495 case-control pairs). The analytical protocols for tocopherol estimation were similar at both facilities and included the deproteinization of serum samples, extraction of tocopherols by an organic solvent, and assay by reversed-phase HPLC using a fluorescent detector. However, there were some differences between the SRL and Kochi methods. The SRL method involved deproteinization by ethanol, extraction by n-hexane, and concentration using nitrogen gas, whereas the Kochi institute method involved deproteinization and extraction by 2-propanol, but no concentration step.

The measurements obtained at SRL were adjusted using the results of 30 samples that were measured by both methods. The regression equations for the values obtained by the 2 methods were \( y_1 = 2.135x_1 - 1.036 \) and \( y_2 = 1.483x_2 + 0.203 \) for \( \alpha \)-tocopherol and \( \gamma \)-tocopherol, respectively, where \( y_1 \) and \( y_2 \) were Kochi method values and \( x_1 \) and \( x_2 \) were SRL method values. The correlation coefficients were 0.903 and 0.970 for \( \alpha \)-tocopherol and \( \gamma \)-tocopherol, respectively.

Serum total cholesterol was measured by an enzymatic method using an automatic analyzer at Kotobiken Medical Laboratories, Inc. (Tokyo, Japan). The standardization of lipid measurement was performed with the aid of the Osaka
Medical Center for Health Science and Promotion, which is an international member of the US National Cholesterol Reference Method Laboratory Network (CRMLN).27

Statistical analysis
Because tocopherols are highly correlated with total cholesterol levels, we used the residual method to adjust α- and γ-tocopherol values for serum total cholesterol.28

To compare the baseline characteristics of mortality cases and control subjects, the paired t-test was used to test mean values, and the McNemar test was used for percentages of cardiovascular risk factors.

Cut-off values in quintile analyses of the distribution of control subjects were determined. Using conditional logistic regression models, odds ratios (ORs) for total stroke, stroke subtype, and coronary heart disease were estimated according to sex-specific quintiles of serum α-tocopherol and γ-tocopherol levels and 1-SD increments in α-tocopherol levels (5.12 µg/ml for men and 6.90 µg/ml for women) and γ-tocopherol levels (0.61 µg/ml for men and 0.67 µg/ml for women). Linear regression was used to test for linear trends across tocopherol categories by using the median tocopherol level for each tocopherol category. Covariates for adjustment included body mass index (categorized as <18.5 kg/m², 18.5–24.9 kg/m², and ≥25 kg/m²), serum total and high-density lipoprotein (HDL) cholesterol levels (mg/dl), cigarette smoking status (never, former, current), alcohol drinking status (never, ex-, and current), walking (≥30 min/day or not), sports (≥5 hour/week or not), and self-reported history of a physician diagnosis of hypertension or diabetes mellitus (yes or no), as well as matching for sex, age, area of residence, tocopherol measurement method, and year of blood drawing.

The data were analyzed with Statistical Analysis Software (SAS; Version 9.1.3 Service Pack 4; SAS Institute, Cary, NC, USA). All probability values for statistical tests were 2-tailed, and a P value less than 0.05 was considered statistically significant.

RESULTS
During the 13-year follow-up, we documented 530 stroke deaths (257 men and 273 women). Of these, 302 deaths (165 men and 137 women) were due to ischemic stroke and 210 (85 men and 125 women) were due to hemorrhagic stroke, whereas 211 deaths (114 men and 97 women) were due to coronary heart disease.

Table 1 shows the sex-specific characteristics of cases and controls. Mean age at death was 67 years among men and 72 years among women for ischemic stroke, 63 years among men and 64 years among women for hemorrhagic stroke, 64 years
Table 2. Sex-specific odds ratios (ORs) and 95% CIs for cardiovascular disease mortality by quintile of total cholesterol-adjusted serum α-tocopherol

| Sex     | Serum α-tocopherol | Q1 (low) | Q2 | Q3 | Q4 | Q5 (high) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | \( P \) for trend | 1-SD increment |
|---------|--------------------|---------|----|----|----|----------|-------------|-------------|-------------|-------------|-------------|----------------|----------------|
| Men     | Median, µg/mL      | 8.7     | 11.1 | 12.8 | 14.7 | 19.5     |              |             |             |             |             |                 |                |
|         | Range, µg/mL       | (1.7–10.2) | (10.2–11.6) | (11.8–13.7) | (13.7–16.3) | (16.3–49.0) |              |             |             |             |             |                 |                |
| Total stroke | No. of cases  | 63     | 52 | 56 | 50 | 56     | 1.00        | 0.61 (0.22–1.56) | 0.92 (0.49–1.70) | 0.92 (0.81–1.17) | 0.98 (0.81–1.17) |                 |                |
|          | No. of controls    | 38     | 31 | 37 | 30 | 38     | 1.00        | 0.63 (0.30–1.33) | 0.85 (0.44–1.63) | 0.81 (0.41–1.60) | 0.87 (0.75–1.11) |                 |                |
| Ischemic stroke | No. of cases  | 38     | 31 | 37 | 30 | 38     | 1.00        | 0.63 (0.26–1.52) | 0.90 (0.38–2.16) | 0.83 (0.35–2.00) | 0.91 (0.70–1.15) |                 |                |
|         | No. of controls    | 23     | 19 | 24 | 15 | 19     | 1.00        | 0.23 (0.07–0.76) | 0.97 (0.34–2.75) | 1.58 (0.55–4.59) | 0.89 (0.29–2.74) | 0.61 (0.76–1.52) |                |
| Coronary heart disease | No. of cases  | 23     | 21 | 23 | 17 | 20     | 1.00        | 0.76 (0.34–1.70) | 0.63 (0.28–1.42) | 0.63 (0.26–1.51) | 0.71 (0.29–1.78) | 0.50 (0.66–1.25) |                |
|         | No. of controls    | 23     | 21 | 23 | 17 | 20     | 1.00        | 0.76 (0.31–1.94) | 0.59 (0.24–1.45) | 0.65 (0.23–1.83) | 0.68 (0.24–1.92) | 0.46 (0.61–1.25) |                |
| Hemorrhagic stroke | No. of cases  | 68     | 52 | 56 | 53 | 60     | 1.00        | 0.70 (0.39–1.25) | 0.48 (0.26–0.92) | 0.61 (0.32–1.20) | 0.39 (0.20–0.78) | 0.01 (0.68–1.08) |                |
|          | No. of controls    | 68     | 52 | 56 | 53 | 60     | 1.00        | 0.70 (0.37–1.34) | 0.44 (0.21–0.91) | 0.52 (0.24–1.01) | 0.37 (0.16–0.77) | 0.009 (0.86–1.10) |                |
| Ischemic stroke | No. of cases  | 37     | 30 | 31 | 25 | 32     | 1.00        | 0.70 (0.39–1.25) | 0.48 (0.26–0.92) | 0.61 (0.32–1.20) | 0.39 (0.20–0.78) | 0.01 (0.68–1.08) |                |
|          | No. of controls    | 37     | 30 | 31 | 25 | 32     | 1.00        | 0.70 (0.37–1.34) | 0.44 (0.21–0.91) | 0.52 (0.24–1.01) | 0.37 (0.16–0.77) | 0.009 (0.86–1.10) |                |
| Coronary heart disease | No. of cases  | 25     | 19 | 21 | 17 | 20     | 1.00        | 1.05 (0.43–2.60) | 0.36 (0.14–0.95) | 0.53 (0.19–1.48) | 0.37 (0.14–0.72) | 0.03 (0.83–1.16) |                |
|          | No. of controls    | 25     | 19 | 21 | 17 | 20     | 1.00        | 1.19 (0.40–3.57) | 0.39 (0.12–1.29) | 0.51 (0.15–1.74) | 0.47 (0.14–1.52) | 0.12 (0.97–1.64) |                |
| Hemorrhagic stroke | No. of cases  | 25     | 19 | 21 | 17 | 20     | 1.00        | 0.57 (0.25–1.32) | 0.76 (0.30–1.91) | 0.87 (0.34–2.23) | 0.38 (0.14–1.09) | 0.15 (0.81–1.18) |                |
|          | No. of controls    | 25     | 19 | 21 | 17 | 20     | 1.00        | 0.61 (0.22–1.74) | 0.74 (0.22–4.46) | 0.62 (0.15–2.05) | 0.26 (0.07–0.97) | 0.048 (0.68–1.05) |                |
| Coronary heart disease | No. of cases  | 25     | 19 | 21 | 17 | 20     | 1.00        | 0.99 (0.40–2.45) | 1.01 (0.39–2.59) | 0.52 (0.18–1.50) | 0.99 (0.36–2.75) | 0.88 (0.69–1.15) |                |
|          | No. of controls    | 25     | 19 | 21 | 17 | 20     | 1.00        | 0.66 (0.18–2.33) | 0.89 (0.25–3.17) | 0.33 (0.08–3.22) | 0.97 (0.24–3.96) | 0.85 (0.62–1.36) |                |

\*Adjusted for body mass index (<18.5, 18.5–24.9, 25s), cigarette smoking status (never, ex-, and current), alcohol drinking status (never, ex-, and current), history of hypertension and diabetes mellitus, walking (≥30 min/day or not), sports (≥5 h/week or not), total cholesterol, and high-density lipoprotein cholesterol (continuous).

Among men and 69 years among women for coronary heart disease. Among cases compared with controls, the prevalence of hypertension was higher in men who had any stroke, ischemic stroke, or coronary heart disease and in women with hemorrhagic stroke; average alcohol intake and prevalence of current smoking were higher in men; the prevalence of current smoking was higher in men with any stroke or ischemic stroke; the prevalence of diabetes mellitus was higher in women with coronary heart disease; mean serum total cholesterol was lower in women with any stroke or hemorrhagic stroke; and mean serum α-tocopherol tended to be lower for all cardiovascular endpoints among both men and women, except for hemorrhagic stroke in men.

In addition, among cases, mean serum γ-tocopherol tended to lower for all cardiovascular endpoints among both men and women, except for coronary heart disease in men and any stroke and hemorrhagic stroke in women.

Table 2 shows age-, sex-, and community-matched ORs and multivariate ORs (95% CIs) for cardiovascular disease mortality according to quintile of serum α-tocopherol levels.
Table 3. Sex-specific odds ratios (ORs) and 95% CIs for cardiovascular disease mortality by quintile of total cholesterol-adjusted serum γ-tocopherol

| Serum γ-tocopherol level | Q1 (low) | Q2 | Q3 | Q4 | Q5 (high) | P for trend | 1-SD increment |
|--------------------------|---------|----|----|----|---------|-----------|--------------|
| Total stroke             |         |    |    |    |         |           |              |
| No. of cases             | 68      | 48 | 49 | 46 | 46      | 0.37      | 0.67–1.04    |
| No. of controls          | 52      | 47 | 52 | 56 | 50      |           |              |
| Age-, community-matched OR | 1.00  | 0.78 | 0.69 | 0.59 | 0.66 | 0.38–1.17 | 0.15 0.84 (0.68–1.03) |
| Multivariable OR         | 1.00    | 0.73 | 0.75 | 0.55 | 0.68 | 0.37–1.25 | 0.21 0.83 (0.67–1.04) |
| Hemorrhagic stroke       |         |    |    |    |         |           |              |
| No. of cases             | 50      | 34 | 30 | 23 | 28      |           |              |
| No. of controls          | 37      | 31 | 33 | 32 | 32      |           |              |
| Age-, community-matched OR | 1.00  | 0.84 | 0.64 | 0.50 | 0.60 | 0.30–1.19 | 0.12 0.80 (0.62–1.04) |
| Multivariable OR         | 1.00    | 0.81 | 0.57 | 0.48 | 0.48 | 0.22–1.09 | 0.07 0.77 (0.58–1.02) |
| Coronary heart disease   |         |    |    |    |         |           |              |
| No. of cases             | 16      | 16 | 19 | 19 | 18      |           |              |
| No. of controls          | 12      | 16 | 19 | 21 | 17      |           |              |
| Age-, community-matched OR | 1.00  | 0.62 | 0.67 | 0.63 | 0.75 | 0.26–2.23 | 0.78 0.93 (0.66–1.31) |
| Multivariable OR         | 1.00    | 0.34 | 0.56 | 0.27 | 0.88 | 0.18–4.31 | 0.73 1.03 (0.65–1.62) |

| Serum γ-tocopherol | Q1 (low) | Q2 | Q3 | Q4 | Q5 (high) | P for trend | 1-SD increment |
|--------------------|---------|----|----|----|---------|-----------|--------------|
| Total stroke       |         |    |    |    |         |           |              |
| No. of cases       | 20      | 20 | 25 | 23 | 26      |           |              |
| No. of controls    | 22      | 27 | 22 | 25 | 25      |           |              |
| Age-, community-matched OR | 1.00  | 0.84 | 1.32 | 1.43 | 1.19 | 0.47–3.00 | 0.64 1.13 (0.89–1.44) |
| Multivariable OR*  | 1.00    | 1.02 | 1.54 | 1.72 | 1.54 | 0.52–2.62 | 0.48 1.20 (0.91–1.57) |

| Serum γ-tocopherol | Q1 (low) | Q2 | Q3 | Q4 | Q5 (high) | P for trend | 1-SD increment |
|--------------------|---------|----|----|----|---------|-----------|--------------|
| Total stroke       |         |    |    |    |         |           |              |
| No. of cases       | 29      | 36 | 20 | 29 | 23      |           |              |
| No. of controls    | 29      | 26 | 26 | 25 | 31      |           |              |
| Age-, community-matched OR | 1.00  | 1.46 | 1.14 | 1.12 | 0.82 | 0.33–2.04 | 0.59 0.84 (0.61–1.16) |
| Multivariable OR*  | 1.00    | 1.19 | 0.72 | 1.00 | 0.83 | 0.33–2.04 | 0.59 0.84 (0.61–1.16) |
| Hemorrhagic stroke |         |    |    |    |         |           |              |
| No. of cases       | 20      | 32 | 21 | 22 | 30      |           |              |
| No. of controls    | 29      | 26 | 26 | 21 | 23      |           |              |
| Age-, community-matched OR | 1.00  | 1.76 | 1.15 | 1.55 | 1.99 | 0.85–4.65 | 0.19 1.26 (0.97–1.65) |
| Multivariable OR*  | 1.00    | 1.44 | 1.82 | 1.62 | 3.10 | 0.05–10.1 | 0.052 1.49 (1.04–2.13) |
| Coronary heart disease |       |    |    |    |         |           |              |
| No. of cases       | 12      | 20 | 20 | 16 | 23      |           |              |
| No. of controls    | 12      | 20 | 20 | 16 | 19      |           |              |
| Age-, community-matched OR | 1.00  | 0.52 | 0.25 | 0.31 | 0.56 | 0.21–1.48 | 0.24 0.85 (0.64–1.13) |
| Multivariable OR*  | 1.00    | 0.66 | 0.27 | 0.23 | 0.57 | 0.15–2.23 | 0.32 0.87 (0.59–1.28) |

*Adjusted for body mass index (<18.5, 18.5–24.9, 25s), cigarette smoking status (never, ex-, and current), alcohol drinking status (never, ex-, and current), history of hypertension and diabetes mellitus, walking ≥30 min/day or not, sports ≥5 h/week or not, and total cholesterol and high-density lipoprotein cholesterol.

In men, there was no association between serum α-tocopherol and cardiovascular disease mortality. In women, serum α-tocopherol was inversely associated with mortality from any stroke and hemorrhagic stroke. The multivariate OR (95% CI) for the highest versus lowest quintile of serum α-tocopherol among women was 0.35 (0.16–0.77; P for trend = 0.009) for total stroke, 0.47 (0.14–1.52; P for trend = 0.12) for ischemic stroke, 0.26 (0.07–0.97; P for trend = 0.048) for hemorrhagic stroke, and 0.97 (0.24–3.95; P for trend = 0.85) for coronary heart disease.

In age-, sex-, and community-matched analyses, there was no significant association between serum γ-tocopherol and mortality from any cardiovascular disease outcome among men (Table 3). After adjusting for cardiovascular risk factors, the association between serum γ-tocopherol and ischemic stroke death was of borderline significance in men: the multivariate ORs (95% CI) for the highest versus the lowest quintile and for a 1-SD increment in γ-tocopherol level were 0.48 (0.22–1.06; P for trend = 0.07) and 0.77 (0.58–1.02), respectively. In women, serum γ-tocopherol was associated...
with increased hemorrhagic stroke mortality. The multivariate OR (95% CIs) for the highest versus the lowest quintile and for a 1-SD increment in \( \gamma \)-tocopherol level were 3.10 (0.95–10.1; \( P \) for trend = 0.052) and 1.49 (1.04–2.13), respectively.

**DISCUSSION**

In this prospective, nested case-control study of Japanese men and women from the general population without diagnosed cardiovascular disease at enrolment, higher baseline serum \( \alpha \)-tocopherol was associated with lower mortality from total stroke and hemorrhagic stroke among women. Serum \( \gamma \)-tocopherol tended to be associated with lower mortality from ischemic stroke among men and higher mortality from hemorrhagic stroke among women. There was no significant association between \( \alpha \)- or \( \gamma \)-tocopherol and coronary heart disease mortality among men or women.

To our knowledge, only 3 studies have investigated the association between blood levels of tocopherols and cardiovascular disease risk among men\(^{18,22} \); however, have been no such studies of women. Our study is the first assessment of the relationship between serum tocopherol levels and cardiovascular disease risk in women.

The Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) study found that serum \( \alpha \)-tocopherol was associated with a decreased risk of ischemic stroke among men: the multivariate relative risk (95% CI) of ischemic stroke for the highest versus the lowest quartile of \( \alpha \)-tocopherol levels was 0.70 (0.55–0.98).\(^{18} \) The ATBC study also reported that serum \( \alpha \)-tocopherol was inversely associated with risk of intracerebral hemorrhage: the multivariate relative risk (95% CI) of intracerebral hemorrhage for the highest versus the lowest quintile of \( \alpha \)-tocopherol levels was 0.45 (0.26–0.77).\(^{18} \)

The Physicians’ Health Study (PHS) reported no association between serum \( \alpha \)- or \( \gamma \)-tocopherol levels and ischemic stroke risk among men.\(^{20} \) Serum \( \alpha \)-tocopherol was not associated with risk of myocardial infarction in PHS\(^{21} \) or The Multiple Risk Factor Intervention Trial,\(^{22} \) while \( \gamma \)-tocopherol was associated with increased risk of myocardial infarction in PHS: the multivariate relative risk (95% CI) for the highest versus the lowest quintile was 2.14 (1.18–3.87; \( P \) for trend = 0.01).\(^{21} \) In the present study, we did not observe an association between serum \( \alpha \)- or \( \gamma \)-tocopherol and coronary heart disease mortality in men or women. These inconsistent findings regarding serum tocopherol levels and myocardial infarction may be due to a paradoxical effect of tocopherol on oxidation. Although tocopherols are known antioxidants, several in vivo studies have reported that excessive concentrations of tocopherol can cause oxidative stress, leading to lipid peroxidation mediated by the tocopherol radical.\(^{29} \)

The antioxidant activity of \( \alpha \)-tocopherol is a potential pathophysiologic mechanism for the inverse association between serum \( \alpha \)-tocopherol and hemorrhagic stroke mortality. A Japanese autopsy study found that 11% of 101 intracerebral hemorrhage cases had cerebral amyloid angiopathy,\(^{30} \) and the prevalence of amyloid angiopathy tended to be higher in women (28.0%) than in men (18.3%).\(^{31} \) In a neuroimaging study in the United States, 2.2% of 460 subarachnoid hemorrhage patients aged 60 years or older had amyloid angiopathy.\(^{32} \) Deposits of the amyloid beta protein cause degeneration of smooth muscle cells of the vascular media.\(^{33} \) In a mice model of amyloid beta deposition, \( \alpha \)-tocopherol supplementation in mice aged 5 to 13 months reduced amyloid beta protein levels and the area of cerebral amyloid deposits in brain tissue, as compared with a control group.\(^{34} \)

Cerebral aneurysm can occur due to the development of chronic inflammation mediated by nuclear factor \( \kappa \)-light-chain-enhancer of activated B cells (NF-\( \kappa \)B),\(^{35} \) which is induced by oxidative stress.\(^{36} \) Cerebral aneurysms in antioxidant-treated rats were 54% smaller than in controls, due to inhibition of NF-\( \kappa \)B activity.\(^{37} \)

The reasons for the absence of an association between \( \alpha \)-tocopherol and mortality from total stroke and its subtypes among men in the present study are unknown, although the lower prevalence of amyloid angiopathy and lower proportion of subarachnoid hemorrhage among men as compared with women might partially explain this finding.

In addition to acting as antioxidants, tocopherols are also inhibitors of platelet aggregation and thrombus formation.\(^{39,40} \) In an animal experiment, time to thrombus formation was 25% longer in rats fed \( \alpha \)-tocopherol and 58% longer in rats fed \( \gamma \)-tocopherol as compared with controls. Platelet aggregation was 16% lower in rats fed \( \alpha \)-tocopherol and 43% lower in rats fed \( \gamma \)-tocopherol as compared with controls.\(^{40} \) In humans, \( \alpha \)-tocopherol supplementation alone reduced serum \( \gamma \)-tocopherol levels,\(^{41} \) while a supplement with equal amounts of \( \alpha \)- and \( \gamma \)-tocopherols raised plasma \( \alpha \)- and \( \gamma \)-tocopherol levels.\(^{42} \) A supplement with mixed tocopherols (100 mg \( \gamma \)-, 40 mg \( \delta \)-, and 20 mg \( \alpha \)-tocopherol; corresponding to a 20 mg \( \alpha \)-tocopherol equivalent) reduced platelet aggregation by 14% as compared with pre-supplementation platelet aggregation values. No change in platelet aggregation was observed in subjects receiving only an \( \alpha \)-tocopherol supplement.\(^{39} \) This inhibitory effect of \( \gamma \)-tocopherol on platelet aggregation and thrombus formation could account for the association between serum \( \gamma \)-tocopherol and reduced ischemic stroke mortality, as well as the association between serum \( \gamma \)-tocopherol and increased hemorrhagic stroke mortality, observed in the present study.

The present study has several strengths. It is the first study to evaluate the prospective association between serum \( \alpha \)- and \( \gamma \)-tocopherol and cardiovascular disease mortality in
women and Japanese men from the general population. The observational design of our study had the advantage of allowing evaluation of long-term use of tocopherol supplements in relation to mortality. Because the participants in the present nested case-control study were recruited throughout Japan, our study results can be generalized to the entire Japanese population.

The present study has several potential limitations. First, serum samples were collected from only approximately 35% of the total participants. However, because there were no apparent differences in age-adjusted mean values or proportions of major cardiovascular risk factors between the participants who did and did not provide serum samples (data not shown), selection bias in our evaluation of the association between serum tocopherol levels and cardiovascular disease mortality is likely to be limited. Second, we did not examine the long-term stability of tocopherols in deeply frozen serum. However, a previous study found that tocopherol was stable for at least 15 years in serum stored at temperatures of −70°C or lower.43 Third, we used only mortality data as an endpoint, which may have led to misclassification of diagnoses. However, use of computed tomography scans has been widespread in Japan since the 1980s, even in local hospitals; thus, it is likely that our use of death certificate records to classify stroke and its subtypes was sufficiently accurate.44 However, approximately one-third of deaths categorized as coronary heart disease on death certificates were misdiagnosed, as demonstrated by validation studies.45 This discrepancy may have partly contributed to the lack of association between serum tocopherols levels and coronary heart disease mortality observed in the present study.

In conclusion, serum α-tocopherol was associated with lower mortality from total and hemorrhagic strokes in women. γ-Tocopherol tended to be associated with lower mortality from ischemic stroke in men and increased mortality from hemorrhagic stroke in women. No association was found between α- or γ-tocopherol and coronary heart disease mortality in men or women. Further studies are required to evaluate the effectiveness of vitamin E in the prevention of cardiovascular disease.

ACKNOWLEDGMENTS

This study was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (Monbusho), Japanese Ministry of Education, Culture, Sports, Science and Technology (Monbu-kagakusho)—grant numbers: 61010076, 62010074, 63010074, 1010068, 2151065, 3151064, 4151063, 5151069, 6279102, 11181101, 14207019, 17015022, 18014011, 19390174 and 20014026 to the Japan Collaborative Cohort (JACC) Study. This research was also supported by a Grant-in-Aid from the Ministry of Health, Labor and Welfare, Health and Labor Sciences research grants (Research on Health Services: H17-Kenkou-007, Comprehensive Research on Cardiovascular Disease and Life-Related Disease: H18-Junkankitou [Seishuu]-Ippan-012, Comprehensive Research on Cardiovascular Disease and Life-Related Disease: H19-Junkankitou [Seishuu]-Ippan-012, Comprehensive Research on Cardiovascular and Life-Style Related Diseases: H20-Junkan kitou [Seishuu]-Ippan-013 and Comprehensive Research on Cardiovascular and Life-Style Related Diseases: H23-Junkankitou [Seishuu]-Ippan-005). The method for tocopherol measurement used at the Public Health Institute of Kochi Prefecture was developed by Prof. Yorihiro Yamamoto (School of Bioscience and Biotechnology, Tokyo University of Technology, Japan). The authors express their sincere appreciation to Dr. Kunio Aoki, Professor Emeritus, Nagoya University School of Medicine and the former chairperson of the JACC Study, to Dr. Haruo Sugano, former director of the Cancer Institute, Tokyo, who greatly contributed to the initiation of the JACC Study, and to Dr. Yoshiyuki Ohno, Professor Emeritus, Nagoya University School of Medicine, who was also a former chairperson of the study. The authors also thank Dr. Tomoyuki Kitagawa of the Cancer Institute of the Japanese Foundation for Cancer Research, also a former chairperson of Grant-in-Aid for Scientific Research on Priority Area “Cancer,” for his valuable support for this study. The complete list of members of the JACC Study is available at http://www.aichi-med-u.ac.jp/jacc/member.html

Conflicts of interest: None declared.

REFERENCES

1. Clarke MW, Burnett JR, Croft KD. Vitamin E in human health and disease. Crit Rev Clin Lab Sci. 2008;45:417–50.
2. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781–6.
3. Leppälä JM, Virtamo J, Fogelholm R, Huttunen JK, Albanes D, Taylor PR, et al. Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. Arterioscler Thromb Vasc Biol. 2000;20:230–5.
4. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2008;300:2123–33.
5. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Vitamin E in the primary prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2005;294:56–65.
6. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:154–60.
7. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, et al; HOPE and HOPE-TOO Trial Investigators. Effects of long-term
vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005;293:1338–47.
8. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993;328:1444–9.
9. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary disease in men. N Engl J Med. 1993;328:1450–6.
10. Vokó Z, Hollander M, Hofman A, Koudstaal PJ, Breteler MM. Dietary antioxidants and the risk of ischemic stroke: the Rotterdam Study. Neurology. 2003;61:1273–5.
11. Del Rio D, Agnoli C, Pellegrini N, Krogh V, Brighenti F, Mazzeo T, et al. Total antioxidant capacity of the diet is associated with lower risk of ischemic stroke in a large Italian cohort. J Nutr. 2011;141:118–23.
12. Yochum LA, Folsom AR, Kushi LH. Intake of antioxidant vitamins and risk of death from stroke in postmenopausal women. Am J Clin Nutr. 2000;72:476–83.
13. Clarke MW, Burnett JR, Wu JH, Hodgson JM, Ledowski T, Yochum LA, et al. Total antioxidant capacity of the diet is associated with lower risk of ischemic stroke in a large Italian cohort. J Nutr. 2011;141:118–23.
14. Cai Y, Konishi T, Han G, Campwala KH, French SW, Wan YJ. The role of hepatocyte RXR alpha in xenobiotic-sensing nuclear receptor-mediated pathways. Eur J Pharm Sci. 2002;15:89–96.
15. Hongo P, Kluth D, Birringer M, Rühl R, Böl GF, Fluger P, et al. Vitamin E supplementation and hepatic drug metabolism in humans. J Cardiovasc Pharmacol. 2009;54:491–6.
16. Landes N, Pfuger P, Kluth D, Birringer M, Rühl R, Böl GF, et al. Vitamin E activates gene expression via the pregnane X receptor. Biochem Pharmacol. 2003:65:269–73.
17. Cai Y, Konishi T, Han G, Campwala KH, French SW, Wan YJ. The role of hepatocyte RXR alpha in xenobiotic-sensing nuclear receptor-mediated pathways. Eur J Pharm Sci. 2002;15:89–96.
18. Brigelius-Flohé R. Induction of drug metabolizing enzymes by vitamin E. J Plant Physiol. 2005;162:797–802.
19. Parker RS, Sontag TJ, Swanson JE. Cytochrome P450A-dependent metabolism of tocopherols and inhibition by sesamin. Biochem Biophys Res Commun. 2000;273:531–4.
20. Leppäälä JM, Virtamo J, Fogelholm R, Albanes D, Heinonen OP. Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. Stroke. 1999;30:2535–40.
21. Wright ME, Lawson KA, Weinstein SJ, Pietinen P, Taylor PR, Virtamo J, et al. Higher baseline serum concentrations of vitamin E are associated with lower total and cause-specific mortality in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am J Clin Nutr. 2006;84:1200–7.
22. Hak AE, Ma J, Powell CB, Campos H, Gaziano JM, Willett WC, et al. Prospective study of plasma carotenoids and tocopherols in relation to risk of ischemic stroke. Stroke. 2004;35:1584–8.
23. Hak AE, Stampfer MJ, Campos H, Sesso HD, Gaziano JM, Willett W, et al. Plasma carotenoids and tocopherols and risk of myocardial infarction in a low-risk population of US male physicians. Circulation. 2003;108:802–7.
24. Evans RW, Shaten BJ, Day BW, Kuller LH. Prospective association between lipid soluble antioxidants and coronary heart disease in men. The Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1998;147:180–6.
25. Tamakoshi A, Suzuki K, Ito Y, Watanabe Y, Inaba Y, Tajima K, et al; JACC Study Group. Selection of cases and controls for the nested case-control study within the Japan Collaborative Cohort Study: the First-wave. Asian Pac J Cancer Prev. 2009;10 Suppl:1–5.
26. Cui R, Iso H, Toyoshima H, Date C, Yamamoto A, Kikuchi S, et al; JACC Study Group. Serum total cholesterol levels and risk of mortality from stroke and coronary heart disease in Japanese: the JACC study. Atherosclerosis. 2007;194:415–20.
27. Nakamura M, Sato S, Shimamoto T. Improvement in Japanese clinical laboratory measurements of total cholesterol and HDL-cholesterol by the US Cholesterol Reference Method Laboratory Network. J Atheroscler Thromb. 2003;10:145–53.
28. Willett WC, Howe GR, Kushi LH. Adjustment for total energy intake in epidemiologic studies. Am J Clin Nutr. 1997;65 Suppl:4120S–31S.
29. Upston JM, Terentis AC, Stocker R. Tocopherol-mediated peroxidation of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement. FASEB J. 1999;13:977–94.
30. Itoh Y, Yamada M, Hayakawa M, Otomo E, Miyatake T. Cerebral amyloid angiopathy: a significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly. J Neurol Sci. 1993;113:135–41.
31. Masuda J, Tanaka K, Ueda K, Omae T. Autopsy study of incidence and distribution of cerebral amyloid angiopathy in Hisayama, Japan. Stroke. 1988;19:205–10.
32. Kumar S, Goddeau RP Jr, Selim MH, Thomas A, Schlaug G, Alhazzani A, et al. Atraumatic convexal subarachnoid hemorrhage: clinical presentation, imaging patterns, and etiologies. Neurology. 2010 Mar 16;74:893–9.
33. Wisniewski HM, Wegiel J, Vorbrot AW, Mazur-Kolecka B, Frackowiak J. Source. Role of perivascular cells and myocytes in vascular amyloidosis. Ann N Y Acad Sci. 2000;903:647–53.
34. Sung S, Yao Y, Uryu K, Yang H, Lee VM, Trojanowski JQ, et al. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer’s disease. FASEB J. 2004;18:323–5.
35. Aoki T, Kataoka H, Shimamura M, Nakagami H, Wakayama K, Moriwaki T, et al. NF-kappaB is a key mediator of cerebral aneurysm formation. Circulation. 2007 Dec 11;116:2830–8.
36. Nagao M, et al. 409
37. Aoki T, Nishimura M, Kataoka H, Ishibashi R, Nozaki K, Hashimoto N. Reactive oxygen species modulate growth of cerebral vascular smooth muscle cells and may contribute to cerebral vasospasm. Lab Invest. 2009;89:730–41.
38. Frackowiak J. Source. Role of perivascular cells and myocytes in vascular amyloidosis. Ann N Y Acad Sci. 2000;903:647–53.
39. Alhazzani A, et al. Atraumatic convexal subarachnoid hemorrhage: clinical presentation, imaging patterns, and etiologies. Neurology. 2010 Mar 16;74:893–9.
40. Wisniewski HM, Wegiel J, Vorbrot AW, Mazur-Kolecka B, Frackowiak J. Source. Role of perivascular cells and myocytes in vascular amyloidosis. Ann N Y Acad Sci. 2000;903:647–53.
41. Alhazzani A, et al. Atraumatic convexal subarachnoid hemorrhage: clinical presentation, imaging patterns, and etiologies. Neurology. 2010 Mar 16;74:893–9.
42. Wisniewski HM, Wegiel J, Vorbrot AW, Mazur-Kolecka B, Frackowiak J. Source. Role of perivascular cells and myocytes in vascular amyloidosis. Ann N Y Acad Sci. 2000;903:647–53.
tion, superoxide activity, platelet aggregation and arterial thrombogenesis. J Am Coll Cardiol. 1999;34:1208–15.
41. Gutierrez AD, de Serna DG, Robinson I, Schade DS. The response of gamma vitamin E to varying dosages of alpha vitamin E plus vitamin C. Metabolism. 2009;58:469–78.
42. Traber MG, Kayden HJ. Preferential incorporation of alpha-tocopherol vs gamma-tocopherol in human lipoproteins. Am J Clin Nutr. 1989;49:517–26.
43. Comstock GW, Alberg AJ, Helzlsouer KJ. Reported effects of long-term freezer storage on concentrations of retinol, betacarotene, and alpha-tocopherol in serum or plasma summarized. Clin Chem. 1993;39:1075–8.
44. Iso H, Jacobs DR Jr, Goldman L. Accuracy of death certificate diagnosis of intracranial hemorrhage and nonhemorrhagic stroke. The Minnesota Heart Survey. Am J Epidemiol. 1990;132:993–8.
45. Yamashita T, Ozawa H, Aono H, Hosokawa H, Saito I, Ikebe T. Heart disease deaths on death certificates re-evaluated by clinical records in a Japanese city. Jpn Circ J. 1997;61:331–8.